uniQure (NASDAQ:QURE) Director Sells $278,500.00 in Stock

uniQure N.V. (NASDAQ:QURE) Director Madhavan Balachandran sold 10,000 shares of uniQure stock in a transaction on Monday, June 15th. The stock was sold at an average price of $27.85, for a total transaction of $278,500.00. Following the sale, the director owned 43,254 shares of the company’s stock, valued at $1,204,623.90. The trade was a 18.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Madhavan Balachandran also recently made the following trade(s):

• On Thursday, June 11th, Madhavan Balachandran sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total value of $53,930.58.

uniQure Stock Performance

QURE traded up $21.17 on Wednesday, reaching $48.16. 19,692,387 shares of the stock were exchanged, compared to its average volume of 2,719,465. The company’s 50-day moving average price is $22.93 and its 200 day moving average price is $21.75. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market capitalization of $3.04 billion, a PE ratio of -13.84 and a beta of 0.98.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. As a group, sell-side analysts forecast that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Institutional Trading of uniQure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Militia Capital Management LLC acquired a new stake in shares of uniQure in the first quarter valued at about $1,540,000. Flax Pond Capital LLC lifted its holdings in uniQure by 3.8% during the 1st quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company’s stock worth $2,486,000 after buying an additional 5,533 shares in the last quarter. Stempoint Capital LP raised its position in shares of uniQure by 79.5% during the 1st quarter. Stempoint Capital LP now owns 78,066 shares of the biotechnology company’s stock worth $1,276,000 after acquiring an additional 34,581 shares in the last quarter. Irenic Capital Management LP acquired a new position in uniQure during the first quarter worth approximately $1,635,000. Finally, Readystate Asset Management LP increased its position in uniQure by 39.6% in the 1st quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company’s stock valued at $8,252,000 after acquiring an additional 143,142 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on QURE shares. HC Wainwright decreased their price objective on shares of uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $15.00 to $60.00 in a research report on Monday, March 9th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and increased their price target for the stock from $11.00 to $35.00 in a research report on Monday, March 9th. Finally, TD Cowen reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.17.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: The FDA signaled that uniQure can use its three-year AMT-130 data as the basis for an accelerated approval filing, improving the odds of a near-term BLA submission. Article Title
• Positive Sentiment: Analysts reacted favorably, with Cantor Fitzgerald upgrading QURE to overweight and raising its price target, reinforcing the idea that the FDA update materially improves the company’s outlook. Article Title
• Positive Sentiment: Heavy call-option buying and unusually high trading volume suggest investors are betting on more upside after the regulatory breakthrough. Article Title
• Neutral Sentiment: Insider Jeannette Potts sold 5,237 shares in a recent SEC-reported transaction, which may slightly temper sentiment but does not change the clinical or regulatory story driving the stock. Article Title

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.